Impulsive behaviours affect patients with major depressive disorder (MDD) and bipolar disorder (BP), increasing suicide risk and mood instability. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has been reported to promote fast-acting antidepressive and antisuicidal effects. Magnesium administered contemporarily with low-dose NMDA antagonists has been shown to cause a reduction...
Ketamine has emerged as a novel treatment for psychiatric disorders, particularly treatment-resistant depression (TRD). Although intravenous (IV) ketamine is not approved by the Food and Drug Administration (FDA) for TRD, esketamine, an FDA-approved therapeutic, has contributed to the widespread clinical use of off-label IV ketamine across the United States. This scoping review highlights...
Iman Attackpour Torik, Mohammad Moeini, Shahram Moghaddam et al.
preprint
Abstract Introduction: Precipitated withdrawal syndrome (POW) occurs when agonist-antagonist opioids are administered to individuals dependent on full agonist opioids. This class of drugs exerts strong antagonistic effects, is associated with mu-opioid receptor depletion, and induces severe withdrawal symptoms in affected patients. Standard management typically involves supportive care and...
Background: Intravenous ketamine and esketamine (ESK) produce rapid antidepressant action in treatment-resistant depression (TRD) patients, however dose response is not known. Study assessed efficacy, dose response and safety of intranasal ESK and ability to sustain response with gradual tapering of treatment frequency. Methods: In the Panel A (conducted in USA and Belgium) of this...
Abstract: A growing body of literature has demonstrated the potential for ketamine in the treatment of major depression. Sub-anesthetic doses produce rapid and sustained changes in depressive behavior, both in patients and rodent models, associated with reorganization of glutamatergic synapses in the prefrontal cortex (PFC). While ketamine is known to regulate NMDA-type glutamate receptors...
BACKGROUND Suicide is among the top 10 leading causes of death worldwide. Of people who died by suicide, the majority are diagnosed with depression. It is estimated that 25%-60% of people with bipolar depression (BD) will attempt suicide at least once, and 10%-15% will die by suicide. Several treatments, such as lithium, clozapine, electroconvulsive therapy, and cognitive behavioral therapy,...
Abstract Background: The critical issue of treating Treatment-Resistant Depression (TRD) is to improve antidepressant effect rapid onset and the recovery rates. Significant antidepressant effects of ketamine onset rapidly, but decay rapidly and repeated dosing increases the risks. This study aimed to explore the efficacy and safety of single intravenous ketamine, combined with venlafaxines...
Aaron Emile Philipp-Muller, Taras Reshetukha, Gustavo Vazquez et al.
BACKGROUND Over one third of patients with posttraumatic stress disorder (PTSD) do not respond to current interventions. Ketamine presents a potential treatment option; however, its effects are temporary. Administering ketamine alongside psychotherapy is one potential means of prolonging its effects; however, only a few studies have investigated this treatment method to date, and none have...
BACKGROUND Major depressive disorder is among the most disabling illnesses worldwide, with a lifetime prevalence of 16.2%. Research suggests that 20% to 40% of patients with depression do not respond to pharmacotherapy, developing treatment-resistant depression. Electroconvulsive therapy is the gold standard for treating individuals with treatment-resistant depression, with remission rates of...
Danika Dai, Courtney Miller, Violeta Valdivia et al.
preprint
Abstract BackgroundKetamine has emerged as a rapid-acting antidepressant in treatment-resistant depression (TRD) increasingly used in non-research, clinical settings. Few studies, however, have examined neurocognitive effects of repeated racemic ketamine infusion treatments in patients with TRD. In an effort to identify potential effects after serial infusions, we conducted a retrospective...